Abstract:To standardize the prevention and clinical management of lung cancer, improve patients' survival outcomes, and offer professional insight for clinicians, the Oncology Society of Chinese Medical Association has summoned experts from departments of pulmonary medicine, oncology, thoracic surgery, radiotherapy, imaging, and pathology to formulate the Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer in China (2023 edition) through consensus meetings. Updates in this edition include 1) cancer screening: deletion of high-risk traits of lung cancer based on epidemiological investigations in the Caucasian population, while preserving features confirmed by research on the Chinese population. Advice on screening institutions is also added to raise awareness of the merits and demerits of lung cancer screening through detailed illustrations. 2) Principles of histopathologic evaluation: characteristics of four types of neuroendocrine tumors (typical carcinoid, atypical carcinoid, large cell carcinoma, and small cell carcinoma) are reviewed. 3) Surgical intervention: more options of resection are available for certain peripheral lesions based on several clinical studies (CALGB140503, JCOG0802, JCOG1211). 4) neoadjuvant/adjuvant therapy: marked improvement in the prognosis of non-small cell lung cancer (NSCLC) patients receiving neoadjuvant immunotherapy are reviewed; more options for consolidation immunotherapy after radiochemotherapy have also emerged. 5) Targeted and immune therapy: tyrosine kinase inhibitors of sensitive driver mutations such as EGFR and ALK as well as rare targets such as MET exon 14 skipping, RET fusion, ROS1 fusion, and NTRK fusion have been approved, offering more treatment options for clinicians and patients. Furthermore, multiple immune checkpoint inhibitors have been granted for the treatment of NSCLC and SCLC, resulting in prolonged survival of late-stage lung cancer patients. This guideline is established based on the current availability of domestically approved medications, recommendations of international guidelines, and present clinical practice in China as well as integration of the latest medical evidence of pathology, genetic testing, immune molecular biomarker detection, and treatment methods of lung cancer in recent years, to provide recommendations for professionals in clinical oncology, radiology, laboratory, and rehabilitation.

CSCO Guidelines for Colorectal Cancer Version 2024: Updates and Discussions.

Update in Version 2021 of CSCO Guidelines for Colorectal Cancer from Version 2020

Updates in Version 2019 of CSCO Guidelines for Colorectal Cancer from Version 2018.

CSCO Guidelines for Colorectal Cancer Version 2022: Updates and Discussions

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Guidelines in 2024: International Contributions from China

[Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer (2023 edition)].

Interpretation of Updated Guidelines for Colorectal Cancer Screening in Average-Risk Individuals in the United States

Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022

Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024

CSCO guidelines for metastatic colorectal cancer: personalized medicine in clinical practice

Chinese national clinical practice guidelines on prevention, diagnosis and treatment of early colorectal cancer

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

[Expert consensus on the early diagnosis and treatment of colorectal cancer in China (2023 edition)]

Current status of rectal cancer treatment in China

The Current Status of Treatment for Colorectal Cancer in China

Interpretation of CSCO melanoma guidelines 2020

Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)]

National Guidelines for Diagnosis and Treatment of Colorectal Cancer 2020 in China (english Version)